gemcitabine has been researched along with nuc-1031 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; Blagden, S; Ghazaly, E; Jiang, WG; Lopez, MH; Mason, M; McGuigan, C; Slusarczyk, M; Thompson, E | 1 |
| Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH | 1 |
| Abdelrahman, A; Arora, M; Barrett, MT; Bogenberger, JM; Borad, MJ; Braggio, E; Chen, X; Egan, JB; Kasimsetty, A; Kosiorek, HE; Leiting, JL; Lenkiewicz, E; Malasi, S; Nagalo, BM; Salomao, MA; Truty, MJ; Uson, PLS; Zhou, Y | 1 |
| Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW | 1 |
1 review(s) available for gemcitabine and nuc-1031
| Article | Year |
|---|---|
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
3 other study(ies) available for gemcitabine and nuc-1031
| Article | Year |
|---|---|
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans | 2014 |
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms | 2019 |
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biliary Tract Neoplasms; Cell Proliferation; Cisplatin; Cytidine Monophosphate; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |